The Principal Scientist position in the Target Generation Unit (TGU) of the Biotherapeutics and Bioinnovation Center (BBC) is responsible for implementing a strategy to identify novel drug targets by discovering rare human DNA sequence variants associated with adverse clinical outcomes. The successful candidate will have a broad understanding of DNA sequencing technologies, and familiarity with analytical techniques for DNA characterization. The successful candidate will apply technical and functional knowledge to design experiments and independently complete work. Significant experience applying DNA sample preparation studies and engineering principles to reduce the time and cost of high-throughput DNA sequencing is essential. The incumbent must have demonstrated productivity in a dynamic collaborative environment. Effective communication skills are essential for directing laboratory scientists and technicians.
Qualifications:
Ph.D. plus >3 years of work experience with high-throughput, single molecule DNA sequencing in the biotechnology industry required. Theoretical and practical knowledge of diverse DNA sample preparation techniques required. Excellent written and verbal communications skills. Demonstrated capability to perform independent research. A strong work ethic, team player and willingness to take on challenging tasks are also required.
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act.
All applicants must have authorization to work for Pfizer in the U.S. In certain circumstances it may be advantageous to Pfizer to support the application(s) for temporary visa classification and/or sponsor applications for permanent residence so that a foreign national colleague can accept or remain in a work assignment in the U. S. For certain classes of temporary visas, the resulting work authorization may be specific to Pfizer and the specific job and/or work site. Pfizer may at its business discretion decide to or refrain from obtaining, maintaining and/or extending the temporary visa status and/or sponsoring a colleague for permanent residency and /or employment eligibility, considering factors such as availability of qualified U.S. workers and the colleague’s long-term prospects for securing lawful permanent residence, among other reasons. Employment applicants requiring immigration sponsorship must disclose, when initial application for employment is made, whether or not they are legally authorized to work for Pfizer in the U.S. and, if so, whether that authorization permits them to work in the job they seek. In no case should Pfizer’s support of a colleague’s temporary visa application or sponsorship of a colleague for permanent residence be construed to guarantee success of that application or amend or otherwise invalidate the “at-will” employment relationship between the colleague and Pfizer.
Benefits:
Throughout our 153 years, a legacy of caring for others has been at the heart of everything we do at Pfizer. This commitment is no less important when it comes to our employees. Pfizer wants to ensure that employees have resources to help them develop and succeed both in their careers and personal lives. One way we can achieve this is
through our comprehensive benefits program, which offers employees and their eligible dependents the variety and flexibility to help address their needs at different stages in life.
Company Profile:
At the Biotherapeutics and Bioinnovation Center (BBC), Pfizer’s independent biotechnology research division, we’re dedicated to looking at diseases in novel ways and discovering new medicines for patients suffering from life-threatening and life-altering diseases. The BBC is a federation of independent research units, each focused on a novel and growing area of biotechnology and utilizing it to develop and deliver a steady pipeline of biotherapeutics. The Target Generation Unit (TGU), located in South San Francisco, is one of the units, which works together with Pfizer Global Research and Development (PGRD) to discover and develop these new medicines, as to improve wellness and quality of life across a range of therapeutic areas.
Please copy and paste the following link into your browser address bar:
http://posttrak.arbita.net/cgi-bin/PostTrak.cgi?RefCode=R6072125806946
